Virginia |
001-09810 | 54-1701843 | |||||||||||||||
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number) |
(I.R.S. Employer
Identification No.)
|
|||||||||||||||
9120 Lockwood Boulevard, |
Mechanicsville |
Virginia |
23116 | ||||||||||||||
(Address of principal executive offices) |
(Zip Code) | ||||||||||||||||
Post Office Box 27626,
Richmond, Virginia
|
23261-7626 |
||||||||||||||||
(Mailing address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||||||||||||
Common Stock, $2 par value per share | OMI | New York Stock Exchange |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 |
Results of Operations and Financial Condition. |
Item 7.01 | Regulation FD Disclosure. |
Item 9.01 |
Financial Statements and Exhibits. |
99.1 | ||||||||
99.2 | ||||||||
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) |
OWENS & MINOR, INC. |
||||||||||||||||||||||||||
Date: August 4, 2023 |
By: |
/s/ Heath H. Galloway |
||||||||||||||||||||||||
Name: |
Heath H. Galloway |
|||||||||||||||||||||||||
Title: |
Executive Vice President, General Counsel and Corporate Secretary |
Financial Summary (1) |
YTD | YTD | |||||||||||||||||||||
($ in millions, except per share data) |
2Q23 |
2Q22 | 2023 | 2022 | |||||||||||||||||||
Revenue |
$2,563 | $2,500 | $5,086 | $4,907 | |||||||||||||||||||
Operating income, GAAP |
$10.8 | $75.1 | $20.6 | $136.1 | |||||||||||||||||||
Adj. Operating Income, Non-GAAP |
$62.0 | $113.6 | $109.7 | $218.5 | |||||||||||||||||||
Net (loss) income, GAAP |
$(28.2) | $28.6 | $(52.7) | $67.9 | |||||||||||||||||||
Adj. Net Income, Non-GAAP |
$14.2 | $58.3 | $17.8 | $131.0 | |||||||||||||||||||
Adj. EBITDA, Non-GAAP |
$112.8 | $163.4 | $221.5 | $285.9 | |||||||||||||||||||
Net (loss) income per common share, GAAP |
$(0.37) | $0.37 | $(0.70) | $0.89 | |||||||||||||||||||
Adj. Net Income per share, Non-GAAP |
$0.18 | $0.76 | $0.23 | $1.72 |
Three Months Ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Net revenue | $ | 2,563,226 | $ | 2,500,015 | |||||||
Cost of goods sold | 2,043,794 | 1,967,510 | |||||||||
Gross margin | 519,432 | 532,505 | |||||||||
Distribution, selling and administrative expenses | 455,030 | 421,925 | |||||||||
Acquisition-related charges and intangible amortization | 22,203 | 37,276 | |||||||||
Exit and realignment charges | 28,963 | 1,214 | |||||||||
Other operating expense (income), net | 2,397 | (2,995) | |||||||||
Operating income | 10,839 | 75,085 | |||||||||
Interest expense, net | 40,728 | 35,839 | |||||||||
Other expense, net | 1,072 | 783 | |||||||||
(Loss) income before income taxes | (30,961) | 38,463 | |||||||||
Income tax (benefit) provision | (2,720) | 9,859 | |||||||||
Net (loss) income | $ | (28,241) | $ | 28,604 | |||||||
Net (loss) income per common share: | |||||||||||
Basic | $ | (0.37) | $ | 0.38 | |||||||
Diluted | $ | (0.37) | $ | 0.37 |
Six Months Ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Net revenue | $ | 5,086,075 | $ | 4,906,967 | |||||||
Cost of goods sold | 4,069,336 | 4,001,014 | |||||||||
Gross margin | 1,016,739 | 905,953 | |||||||||
Distribution, selling and administrative expenses | 903,752 | 691,397 | |||||||||
Acquisition-related charges and intangible amortization | 44,392 | 79,410 | |||||||||
Exit and realignment charges | 44,637 | 2,896 | |||||||||
Other operating expense (income), net | 3,312 | (3,894) | |||||||||
Operating income | 20,646 | 136,144 | |||||||||
Interest expense, net | 82,926 | 47,858 | |||||||||
Other expense, net | 2,458 | 1,565 | |||||||||
(Loss) income before income taxes | (64,738) | 86,721 | |||||||||
Income tax (benefit) provision | (12,079) | 18,837 | |||||||||
Net (loss) income | $ | (52,659) | $ | 67,884 | |||||||
Net (loss) income per common share: | |||||||||||
Basic | $ | (0.70) | $ | 0.92 | |||||||
Diluted | $ | (0.70) | $ | 0.89 |
June 30, | December 31, | ||||||||||
2023 | 2022 | ||||||||||
Assets | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 286,307 | $ | 69,467 | |||||||
Accounts receivable, net of allowances of $9,270 and $9,063 |
672,511 | 763,497 | |||||||||
Merchandise inventories | 1,168,227 | 1,333,585 | |||||||||
Other current assets | 135,409 | 128,636 | |||||||||
Total current assets | 2,262,454 | 2,295,185 | |||||||||
Property and equipment, net of accumulated depreciation of $510,394 and $450,286 |
559,508 | 578,269 | |||||||||
Operating lease assets | 292,809 | 280,665 | |||||||||
Goodwill | 1,637,149 | 1,636,705 | |||||||||
Intangible assets, net | 403,020 | 445,042 | |||||||||
Other assets, net | 133,060 | 150,417 | |||||||||
Total assets | $ | 5,288,000 | $ | 5,386,283 | |||||||
Liabilities and equity | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 1,194,173 | $ | 1,147,414 | |||||||
Accrued payroll and related liabilities | 92,264 | 93,296 | |||||||||
Other current liabilities | 405,204 | 325,756 | |||||||||
Total current liabilities | 1,691,641 | 1,566,466 | |||||||||
Long-term debt, excluding current portion | 2,309,853 | 2,482,968 | |||||||||
Operating lease liabilities, excluding current portion of $86,437 and $76,805 | 214,905 | 215,469 | |||||||||
Deferred income taxes | 55,354 | 60,833 | |||||||||
Other liabilities | 120,018 | 114,943 | |||||||||
Total liabilities | 4,391,771 | 4,440,679 | |||||||||
Total equity | 896,229 | 945,604 | |||||||||
Total liabilities and equity | $ | 5,288,000 | $ | 5,386,283 |
Three Months Ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Operating activities: | |||||||||||
Net (loss) income | $ | (28,241) | $ | 28,604 | |||||||
Adjustments to reconcile net (loss) income to cash provided by operating activities: | |||||||||||
Depreciation and amortization | 72,062 | 73,161 | |||||||||
Share-based compensation expense | 5,212 | 5,807 | |||||||||
Benefit for losses on accounts receivable | (379) | (1,116) | |||||||||
Loss on extinguishment of debt | 279 | — | |||||||||
Deferred income tax benefit | (6,167) | 1,670 | |||||||||
Changes in operating lease right-of-use assets and lease liabilities | (2,852) | 1,068 | |||||||||
(Gain) loss on sale and dispositions of property and equipment | (10,294) | 226 | |||||||||
Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
Accounts receivable | 84,963 | 29,194 | |||||||||
Merchandise inventories | 119,819 | (82,536) | |||||||||
Accounts payable | 29,077 | 19,316 | |||||||||
Net change in other assets and liabilities | 46,471 | 9,220 | |||||||||
Other, net | 3,162 | 5,210 | |||||||||
Cash provided by operating activities | 313,112 | 89,824 | |||||||||
Investing activities: | |||||||||||
Acquisition, net of cash acquired | — | (108,329) | |||||||||
Additions to property and equipment | (46,600) | (52,627) | |||||||||
Additions to computer software | (2,889) | (2,111) | |||||||||
Proceeds from sale of property and equipment | 18,423 | 5,843 | |||||||||
Other, net | (418) | (839) | |||||||||
Cash used for investing activities | (31,484) | (158,063) | |||||||||
Financing activities: | |||||||||||
Borrowings under amended Receivables Financing Agreement | 116,100 | 347,800 | |||||||||
Repayments under amended Receivables Financing Agreement | (116,100) | (402,800) | |||||||||
Repayments of debt | (51,801) | (1,500) | |||||||||
Borrowings under revolving credit facility, net and Receivables Financing Agreement | — | (11,700) | |||||||||
Financing costs paid | — | (7,735) | |||||||||
Other, net | (3,830) | (7,625) | |||||||||
Cash used for by financing activities | (55,631) | (83,560) | |||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (88) | (3,195) | |||||||||
Net increase (decrease) in cash, cash equivalents and restricted cash | 225,909 | (154,994) | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 83,194 | 228,023 | |||||||||
Cash, cash equivalents and restricted cash at end of period(1) |
$ | 309,103 | $ | 73,029 | |||||||
Supplemental disclosure of cash flow information: | |||||||||||
Income taxes (received) paid, net | $ | (12,911) | $ | 21,304 | |||||||
Interest paid | $ | 46,089 | $ | 19,791 | |||||||
Noncash investing activity: | |||||||||||
Unpaid purchases of property and equipment and computer software at end of period | $ | 65,808 | $ | 56,429 |
Six Months Ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Operating activities: | |||||||||||
Net (loss) income | $ | (52,659) | $ | 67,884 | |||||||
Adjustments to reconcile net (loss) income to cash provided by operating activities: | |||||||||||
Depreciation and amortization | 142,988 | 97,286 | |||||||||
Share-based compensation expense | 11,675 | 11,210 | |||||||||
(Benefit) provision for losses on accounts receivable | (900) | 4,512 | |||||||||
Loss on extinguishment of debt | 843 | — | |||||||||
Deferred income tax (benefit) provision | (6,758) | 1,601 | |||||||||
Changes in operating lease right-of-use assets and lease liabilities | (3,077) | 606 | |||||||||
(Gain) loss on sale and dispositions of property and equipment | (18,563) | 226 | |||||||||
Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
Accounts receivable | 90,203 | 16,275 | |||||||||
Merchandise inventories | 165,651 | (24,438) | |||||||||
Accounts payable | 52,159 | 12,349 | |||||||||
Net change in other assets and liabilities | 82,954 | (23,945) | |||||||||
Other, net | 6,994 | 5,958 | |||||||||
Cash provided by operating activities | 471,510 | 169,524 | |||||||||
Investing activities: | |||||||||||
Acquisition, net of cash acquired | — | (1,684,607) | |||||||||
Additions to property and equipment | (92,750) | (62,236) | |||||||||
Additions to computer software | (8,229) | (3,463) | |||||||||
Proceeds from sale of property and equipment | 35,729 | 5,846 | |||||||||
Other, net | (418) | (839) | |||||||||
Cash used for investing activities | (65,668) | (1,745,299) | |||||||||
Financing activities: | |||||||||||
Borrowings under amended Receivables Financing Agreement | 348,200 | 347,800 | |||||||||
Repayments under amended Receivables Financing Agreement | (444,200) | (402,800) | |||||||||
Repayments of debt | (78,301) | (1,500) | |||||||||
Proceeds from issuance of debt | — | 1,691,000 | |||||||||
Borrowings under revolving credit facility, net and Receivables Financing Agreement | — | 30,000 | |||||||||
Financing costs paid | — | (41,479) | |||||||||
Other, net | (8,819) | (42,388) | |||||||||
Cash (used for) provided by financing activities | (183,120) | 1,580,633 | |||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 196 | (3,864) | |||||||||
Net increase in cash, cash equivalents and restricted cash | 222,918 | 994 | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 86,185 | 72,035 | |||||||||
Cash, cash equivalents and restricted cash at end of period(1) |
$ | 309,103 | $ | 73,029 | |||||||
Supplemental disclosure of cash flow information: | |||||||||||
Income taxes (received) paid, net | $ | (10,506) | $ | 25,782 | |||||||
Interest paid | $ | 78,625 | $ | 32,417 | |||||||
Noncash investing activity: | |||||||||||
Unpaid purchases of property and equipment and computer software at end of period | $ | 65,808 | $ | 56,429 |
Three Months Ended June 30, | |||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
% of | % of | ||||||||||||||||||||||
consolidated | consolidated | ||||||||||||||||||||||
Amount | net revenue | Amount | net revenue | ||||||||||||||||||||
Net revenue: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 1,930,723 | 75.32 | % | $ | 1,927,388 | 77.10 | % | |||||||||||||||
Patient Direct | 632,503 | 24.68 | % | 572,627 | 22.90 | % | |||||||||||||||||
Consolidated net revenue | $ | 2,563,226 | 100.00 | % | $ | 2,500,015 | 100.00 | % | |||||||||||||||
% of segment | % of segment | ||||||||||||||||||||||
Operating income: | net revenue | net revenue | |||||||||||||||||||||
Products & Healthcare Services | $ | 2,940 | 0.15 | % | $ | 61,243 | 3.18 | % | |||||||||||||||
Patient Direct | 59,065 | 9.34 | % | 52,332 | 9.14 | % | |||||||||||||||||
Acquisition-related charges and intangible amortization | (22,203) | (37,276) | |||||||||||||||||||||
Exit and realignment charges | (28,963) | (1,214) | |||||||||||||||||||||
Consolidated operating income | $ | 10,839 | 0.42 | % | $ | 75,085 | 3.00 | % | |||||||||||||||
Depreciation and amortization: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 18,772 | $ | 19,209 | |||||||||||||||||||
Patient Direct | 53,290 | 53,952 | |||||||||||||||||||||
Consolidated depreciation and amortization | $ | 72,062 | $ | 73,161 | |||||||||||||||||||
Capital expenditures: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 6,602 | $ | 18,418 | |||||||||||||||||||
Patient Direct | 42,887 | 36,320 | |||||||||||||||||||||
Consolidated capital expenditures | $ | 49,489 | $ | 54,738 |
Six Months Ended June 30, | |||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
% of | % of | ||||||||||||||||||||||
consolidated | consolidated | ||||||||||||||||||||||
Amount | net revenue | Amount | net revenue | ||||||||||||||||||||
Net revenue: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 3,846,212 | 75.62 | % | $ | 4,061,429 | 82.77 | % | |||||||||||||||
Patient Direct | 1,239,863 | 24.38 | % | 845,538 | 17.23 | % | |||||||||||||||||
Consolidated net revenue | $ | 5,086,075 | 100.00 | % | $ | 4,906,967 | 100.00 | % | |||||||||||||||
% of segment | % of segment | ||||||||||||||||||||||
Operating income: | net revenue | net revenue | |||||||||||||||||||||
Products & Healthcare Services | $ | 4,761 | 0.12 | % | $ | 150,325 | 3.70 | % | |||||||||||||||
Patient Direct | 104,914 | 8.46 | % | 68,125 | 8.06 | % | |||||||||||||||||
Acquisition-related charges and intangible amortization | (44,392) | (79,410) | |||||||||||||||||||||
Exit and realignment charges | (44,637) | (2,896) | |||||||||||||||||||||
Consolidated operating income | $ | 20,646 | 0.41 | % | $ | 136,144 | 2.77 | % | |||||||||||||||
Depreciation and amortization: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 37,338 | $ | 38,203 | |||||||||||||||||||
Patient Direct | 105,650 | 59,083 | |||||||||||||||||||||
Consolidated depreciation and amortization | $ | 142,988 | $ | 97,286 | |||||||||||||||||||
Capital expenditures: | |||||||||||||||||||||||
Products & Healthcare Services | $ | 12,934 | $ | 29,061 | |||||||||||||||||||
Patient Direct | 88,045 | 36,638 | |||||||||||||||||||||
Consolidated capital expenditures | $ | 100,979 | $ | 65,699 |
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Net (loss) income | $ | (28,241) | $ | 28,604 | $ | (52,659) | $ | 67,884 | |||||||||||||||
Weighted average shares outstanding - basic | 75,801 | 74,710 | 75,559 | 74,158 | |||||||||||||||||||
Dilutive shares | — | 1,587 | — | 2,011 | |||||||||||||||||||
Weighted average shares outstanding - diluted | 75,801 | 76,297 | 75,559 | 76,169 | |||||||||||||||||||
Net (loss) income per common share: | |||||||||||||||||||||||
Basic | $ | (0.37) | $ | 0.38 | $ | (0.70) | $ | 0.92 | |||||||||||||||
Diluted | $ | (0.37) | $ | 0.37 | $ | (0.70) | $ | 0.89 |
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
Operating income, as reported (GAAP) | $ | 10,839 | $ | 75,085 | $ | 20,646 | $ | 136,144 | ||||||||||||||||||
Acquisition-related charges and intangible amortization (1) |
22,203 | 37,276 | 44,392 | 79,410 | ||||||||||||||||||||||
Exit and realignment charges (2) |
28,963 | 1,214 | 44,637 | 2,896 | ||||||||||||||||||||||
Operating income, adjusted (non-GAAP) (Adjusted Operating Income) | $ | 62,005 | $ | 113,575 | $ | 109,675 | $ | 218,450 | ||||||||||||||||||
Operating income as a percent of net revenue (GAAP) | 0.42% | 3.00% | 0.41% | 2.77% | ||||||||||||||||||||||
Adjusted operating income as a percent of net revenue (non-GAAP) | 2.42% | 4.54% | 2.16% | 4.45% | ||||||||||||||||||||||
Net (loss) income, as reported (GAAP) | $ | (28,241) | $ | 28,604 | $ | (52,659) | $ | 67,884 | ||||||||||||||||||
Pre-tax adjustments: | ||||||||||||||||||||||||||
Acquisition-related charges and intangible amortization (1) |
22,203 | 37,276 | 44,392 | 79,410 | ||||||||||||||||||||||
Exit and realignment charges (2) |
28,963 | 1,214 | 44,637 | 2,896 | ||||||||||||||||||||||
Other (3) |
843 | 525 | 1,972 | 1,049 | ||||||||||||||||||||||
Income tax benefit on pre-tax adjustments (4) |
(9,551) | (9,358) | (20,530) | (20,225) | ||||||||||||||||||||||
Net income, adjusted (non-GAAP) (Adjusted Net Income) | $ | 14,217 | $ | 58,261 | $ | 17,812 | $ | 131,014 | ||||||||||||||||||
Net (loss) income per common share, as reported (GAAP) | $ | (0.37) | $ | 0.37 | $ | (0.70) | $ | 0.89 | ||||||||||||||||||
After-tax adjustments: | ||||||||||||||||||||||||||
Acquisition-related charges and intangible amortization (1) |
0.24 | 0.37 | 0.45 | 0.79 | ||||||||||||||||||||||
Exit and realignment charges (2) |
0.30 | 0.01 | 0.46 | 0.03 | ||||||||||||||||||||||
Other (3) |
0.01 | 0.01 | 0.02 | 0.01 | ||||||||||||||||||||||
Net income per common share, adjusted (non-GAAP) (Adjusted EPS) | $ | 0.18 | $ | 0.76 | $ | 0.23 | $ | 1.72 |
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
Net (loss) income, as reported (GAAP) | $ | (28,241) | $ | 28,604 | $ | (52,659) | $ | 67,884 | ||||||||||||||||||
Income tax (benefit) provision | (2,720) | 9,859 | (12,079) | 18,837 | ||||||||||||||||||||||
Interest expense, net | 40,728 | 35,839 | 82,926 | 47,858 | ||||||||||||||||||||||
Acquisition-related charges and intangible amortization (1) |
22,203 | 37,276 | 44,392 | 79,410 | ||||||||||||||||||||||
Exit and realignment charges (2) |
28,963 | 1,214 | 44,637 | 2,896 | ||||||||||||||||||||||
Other depreciation and amortization (5) |
50,737 | 42,273 | 100,726 | 56,129 | ||||||||||||||||||||||
Stock compensation (6) |
4,796 | 5,624 | 11,146 | 10,220 | ||||||||||||||||||||||
LIFO (credits) and charges (7) |
(4,534) | 2,136 | 406 | 1,628 | ||||||||||||||||||||||
Other (3) |
843 | 525 | 1,972 | 1,049 | ||||||||||||||||||||||
Adjusted EBITDA (non-GAAP) | $ | 112,775 | $ | 163,350 | $ | 221,467 | $ | 285,911 | ||||||||||||||||||
June 30, | ||||||||
2023 | ||||||||
Total debt, as reported (GAAP) | $ | 2,334,256 | ||||||
Cash and cash equivalents | (286,307) | |||||||
Net debt (non-GAAP) | $ | 2,047,949 | ||||||